心肌梗死后双联抗血小板治疗中质子泵抑制剂与上消化道出血风险降低相关
基于丹麦全国登记数据,纳入46 301例心肌梗死后出院7天内使用双联抗血小板治疗且未抗凝的患者,采用多因素Cox回归分析质子泵抑制剂(PPI)与上消化道出血风险的关系。结果显示PPI使用与上消化道出血风险比0.62(95%CI 0.48-0.77)相关,绝对风险差0.44%(95%CI 0.39-0.48%);但仅35%的高危患者接受了指南推荐的PPI治疗。
要点
- 心肌梗死后双联抗血小板治疗患者中,PPI使用与上消化道出血风险降低相关(风险比0.62)。
- 仅35%的上消化道出血高危患者接受了指南推荐的PPI治疗。
- 总体出血风险较低,应更关注识别最能从PPI治疗中获益的患者。
核心结论
- 心肌梗死后双联抗血小板治疗患者中PPI使用低于指南建议,且PPI总体与上消化道出血风险降低相关。
- 考虑到总体出血风险较低,应更关注识别最能从PPI治疗中获益的患者。
研究设计与样本
- 链接丹麦全国登记数据,识别心肌梗死后出院7天内使用双联抗血小板治疗的患者,排除抗凝治疗者。
- 共纳入46 301例心肌梗死后使用双联抗血小板治疗的患者。
- 采用多因素Cox回归模型计算与PPI使用相关的上消化道出血平均风险,并按指南风险评估比较相关治疗效力。
主要发现
- 仅35%的上消化道出血较高风险患者接受了基于指南标准的推荐PPI治疗。
- 1年上消化道出血风险总体为1.0%(95%CI 0.9-1.1%),高危患者为1.7%(95%CI 1.5-2.0%)。
- PPI与非治疗相比,上消化道出血风险比为0.62(95%CI 0.48-0.77),绝对风险差为0.44%(95%CI 0.39-0.48%)。
- 高危患者中PPI治疗的绝对风险差相似,为0.47%(95%CI 0.43-0.51%)。
临床怎么用
- 心肌梗死后双联抗血小板治疗患者中,可依据指南风险评估识别上消化道出血高危患者并考虑PPI治疗。
- 当前高危患者PPI使用率仅35%,存在指南推荐与实践之间的差距。
- 因总体出血风险较低,应更聚焦于识别最能从PPI治疗中获益的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Guidelines differ in their recommendations on therapy to prevent gastrointestinal bleeding for patients treated with dual antiplatelet treatment (DAPT). We sought to investigate the effectiveness of proton pump inhibitors (PPIs) to prevent upper gastrointestinal (UGI) bleeding in patients using DAPT following myocardial infarction (MI) in relation to current European Society of Cardiology guidelines recommendations. METHODS AND RESULTS: We linked Danish nationwide registries to identify patients taking DAPT 7 days following hospital discharge for an acute MI, and excluded individuals on anticoagulation therapy. We used multiple Cox regression modelling, to compute average risk of UGI bleeding in relation to PPI use. The associated treatment efficacy was compared based on guideline risk assessment. We studied 46 301 patients on DAPT after MI. Only 35% of patients at higher risk of UGI bleeding received recommended treatment with a PPI based on the guideline criteria. The 1--year risk of UGI bleeding was 1.0% [95% confidence interval (CI) 0.9-1.1%] and 1.7% (CI 1.5-2.0%) for high-risk patients. Overall PPI compared with no therapy, was associated with a risk ratio for UGI bleeding of 0.62 (CI 0.48-0.77) corresponding to an absolute risk difference of 0.44% (CI 0.39-0.48%). Proton pump inhibitor therapy was associated with a similar absolute risk difference [0.47% (CI 0.43-0.51%)] for high-risk patients. CONCLUSION: Proton pump inhibitor therapy is used less than suggested by guidelines in patients treated with DAPT following MI and was generally associated with reduced risk of UGI bleeding. Considering the overall low risk of bleeding, more focus should be on identifying patients benefiting the most from PPI therapy.
引用
- Sehested TSG, Carlson N, Hansen PW, et al. Reduced risk of gastrointestinal bleeding associated with proton pump inhibitor therapy in patients treated with dual antiplatelet therapy after myocardial infarction. Eur Heart J. 2019. PMID: 30851041. doi:10.1093/eurheartj/ehz104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。